No Data
No Data
Sector Update: Health Care Stocks Advance Premarket Thursday
Health care stocks were advancing premarket Thursday, with the Health Care Select Sector SPDR Fund (XLV) up 0.1% and the iShares Biotechnology ETF (IBB) recently 0.5% higher. Akebia Therapeutics (AKBA
Hutchmed Says Supplemental New Drug Application for Savolitinib Accepted for Review in China
Hutchmed (HCM) said late Wednesday the China National Medical Products Administration has accepted for review its supplemental new drug application for savolitinib as a treatment for adult patients wi
On Wednesday, HUTCHMED Announced Savolitinib SNDA Accepted in China For Treatment-Naïve Or Previously Treated Patients With Locally Advanced Or Metastatic MET Exon 14 NSCLC
HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that the supplemental New Drug Application ("sNDA") for savolitinib, in adult patients with locally advanced or metastat
Do Its Financials Have Any Role To Play In Driving HUTCHMED (China) Limited's (LON:HCM) Stock Up Recently?
HUTCHMED Announces Savolitinib SNDA Accepted in China for Treatment-Naïve or Previously Treated Patients With Locally Advanced or Metastatic MET Exon 14 NSCLC
HUTCHMED today announces that the supplemental New Drug Application ("sNDA") for savolitinib, in adult patients with locally advanced or metastatic non-small cell lung cancer ("NSCLC") with mesenchymal epithelial transition factor ("MET") exon 14 skipping alteration, has been accepted for review by the China National Medical Products Administration (NMPA).
Changes in Hong Kong stocks | Hutchison Pharmaceutical (00013) is now up more than 4%, and the company has initiated the phase II/III study registration phase of solepinib to treat anemia
Hewang Pharmaceutical (00013) is now up more than 4%. As of press release, it has risen 4.4% to HK$27.3, with a turnover of HK$30.6461 million.
No Data